Delving into the Latest Updates on Genus Oncology LLC with Synapse

This research study is studying a combination of targeted therapies known as GO-203-2C and bortezomib as a possible treatment for multiple myeloma that has either progressed or not responded to treatment.

开始日期-

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+2]

NCT01279603

/ Completed临床1期

A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GO-203-2c Given Intravenously Daily X21 Repeated Every 28 Days in Patients With Advanced Solid Tumors Including Lymphomas

This clinical trial is about testing GO-203-2c, which is a newly discovered compound that binds to an oncoprotein (a cancer causing protein) called MUC1 (which is over-expressed in many cancers). By binding to MUC1, GO-203-2c eventually causes tumor cell death in laboratory studies.
This study is being done to:
Test the safety of GO-203-2c and see what effects (good and bad) it has on you and your cancer
Find the highest dose of GO-203-2c that can be given without causing bad side effects
Examine how much GO-203-2c is in the blood at certain times after it is given and how quickly the body gets rid of it
Observe whether there is any effect of GO-203-2c on the size and activity of cancer in your body

开始日期2011-01-01

申办/合作机构

Genus Oncology LLC

100 项与 Genus Oncology LLC 相关的临床结果

登录后查看更多信息

0 项与 Genus Oncology LLC 相关的专利（医药）

登录后查看更多信息

57

项与 Genus Oncology LLC 相关的文献（医药）

2021-09-24·Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

Faculty Opinions recommendation of The SIRPα-CD47 immune checkpoint in NK cells.

作者: Kharbanda, Surender